This finding is in line with that of Yildirim et al. who recently reported a lack of knowledge about the long-term efficacy of anti-IL-1 drugs and suggesting the administration of a maximal tolerated dose of colchicine to FMF patients treated with IL-1 antagonists (108). The gene discussed is IL1B; the disease is familial Mediterranean fever.